Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$7.94 +0.8%	$6.91	$2.32 ▼ $10.13	$425.36M	2.37	900,000 shs	227,058 shs
SVRA Savara	$2.34 +1.3%	$2.42	$1.89 ▼ $4.88	$399.25M	0.31	1.26 million shs	741,297 shs
TCRX TScan Therapeutics	$1.89 +4.4%	$1.53	$1.02 ▼ $7.64	$102.43M	0.97	409,288 shs	380,352 shs
TECX Tectonic Therapeutic	$23.28 +3.1%	$21.60	$13.70 ▼ $61.07	$421.44M	3.17	190,873 shs	156,896 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	+0.76%	-0.87%	+23.48%	+141.34%	-5.02%
SVRA Savara	+1.30%	+1.74%	+14.71%	-22.26%	-51.05%
TCRX TScan Therapeutics	+4.42%	+2.72%	+22.73%	+31.25%	-74.29%
TECX Tectonic Therapeutic	+3.15%	+7.18%	+13.51%	+36.78%	+34.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.5989 of 5 stars	1.3	2.0	2.1	2.5	0.0
SVRA Savara	2.163 of 5 stars	3.3	0.0	2.7	3.3	0.6
TCRX TScan Therapeutics	3.6843 of 5 stars	3.5	5.0	2.6	3.3	0.6
TECX Tectonic Therapeutic	2.9834 of 5 stars	3.7	1.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-20.83% Downside
SVRA Savara	2.60	Moderate Buy	$5.60	139.32% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	312.70% Upside
TECX Tectonic Therapeutic	3.33	Buy	$83.60	259.11% Upside

Current Analyst Ratings Breakdown

Latest TCRX, SVRA, TECX, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/29/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.00
5/28/2025	SVRA Savara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$3.00 ➝ $2.00
5/28/2025	SVRA Savara	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $8.00
5/28/2025	SVRA Savara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	5.36	N/A	N/A	$4.51 per share	1.76
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A
TCRX TScan Therapeutics	$2.82M	37.93	N/A	N/A	$4.26 per share	0.44
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
SVRA Savara	-$95.88M	-$0.48	N/A	N/A	N/A	N/A	-65.88%	-52.35%	8/11/2025 (Estimated)
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-2,974.08%	-55.76%	-36.56%	8/11/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)

Latest TCRX, SVRA, TECX, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TECX Tectonic Therapeutic	-$0.98	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q1 2025	SVRA Savara	-$0.12	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	TCRX TScan Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	28.71	28.71
SVRA Savara	0.20	14.91	14.91
TCRX TScan Therapeutics	0.15	8.55	8.55
TECX Tectonic Therapeutic	N/A	22.92	22.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
SVRA Savara	87.93%
TCRX TScan Therapeutics	82.83%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
SVRA Savara	5.33%
TCRX TScan Therapeutics	4.35%
TECX Tectonic Therapeutic	38.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
SVRA Savara	20	172.84 million	163.63 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	54.13 million	Not Optionable
TECX Tectonic Therapeutic	120	18.67 million	11.58 million	N/A

TCRX, SVRA, TECX, and FULC Headlines

Recent News About These Companies

Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Wall Street Zen

July 5, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - Nasdaq

July 1, 2025 | nasdaq.com

Tectonic Therapeutic joins Russell 3000 index

June 30, 2025 | msn.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution

June 30, 2025 | quiverquant.comQ

Tectonic Therapeutic Joins Russell 3000® Index

June 30, 2025 | globenewswire.com

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25, 2025 | msn.com

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street Zen

June 21, 2025 | marketbeat.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

Tectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock News

June 5, 2025 | gurufocus.com

Tectonic Therapeutic Reports Q1 2025 Financial Results

May 30, 2025 | tipranks.com

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

May 22, 2025 | tipranks.com

Tectonic Therapeutic Announces Phase 1b Trial Results

May 19, 2025 | tipranks.com

Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic

May 19, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)

May 17, 2025 | theglobeandmail.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...

May 17, 2025 | gurufocus.com

Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

May 17, 2025 | quiverquant.comQ

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure

May 17, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, SVRA, TECX, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$7.94 +0.06 (+0.76%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$8.10 +0.17 (+2.08%)

As of 09:16 AM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Savara NASDAQ:SVRA

$2.34 +0.03 (+1.30%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$2.36 +0.02 (+0.85%)

As of 08:48 AM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

TScan Therapeutics NASDAQ:TCRX

$1.89 +0.08 (+4.42%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$1.90 +0.01 (+0.26%)

As of 09:24 AM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Tectonic Therapeutic NASDAQ:TECX

$23.28 +0.71 (+3.15%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$23.26 -0.02 (-0.09%)

As of 07/17/2025 05:43 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time